Skip to main content
. Author manuscript; available in PMC: 2012 Aug 30.
Published in final edited form as: Gut. 2010 Oct 22;60(4):449–455. doi: 10.1136/gut.2010.226860

Figure 5. Correlation of IL-13 Production with Ulcerative Colitis Clinical Activity.

Figure 5

This patient received two courses of interferon-β-1a. The solid line charts the SCCAI decreasing to clinical remission (SCCAI ≤ 2) during treatment (shaded area) and follow-up and indicating a relapse of symptoms at Week 36. Serial measurements of IL-13 production (dotted line) show that it declines with induction of remission and increased in conjunction with clinical relapse.